Leerink Partnrs Issues Negative Estimate for Humana Earnings

Humana Inc. (NYSE:HUM) – Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for shares of Humana in a research report issued on Tuesday, February 11th. Leerink Partnrs analyst W. Mayo now forecasts that the insurance provider will post earnings of $16.51 per share for the year, down from their prior estimate of $16.86. The consensus estimate for Humana’s current full-year earnings is $16.11 per share. Leerink Partnrs also issued estimates for Humana’s Q2 2026 earnings at $5.51 EPS, Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at $15.81 EPS, FY2027 earnings at $27.79 EPS, FY2028 earnings at $36.69 EPS and FY2029 earnings at $45.87 EPS.

HUM has been the topic of several other research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $283.00 target price on shares of Humana in a research note on Wednesday. Morgan Stanley dropped their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Wells Fargo & Company cut their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Truist Financial boosted their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Finally, Piper Sandler increased their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Humana currently has a consensus rating of “Hold” and an average price target of $292.26.

Humana Price Performance

NYSE:HUM opened at $259.93 on Thursday. The firm has a market capitalization of $31.30 billion, a price-to-earnings ratio of 23.02, a PEG ratio of 2.11 and a beta of 0.56. The business has a 50 day simple moving average of $272.44 and a 200-day simple moving average of $295.47. Humana has a 1 year low of $213.31 and a 1 year high of $406.46. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On Humana

Several large investors have recently bought and sold shares of the company. Creative Financial Designs Inc. ADV lifted its position in Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in Humana during the third quarter worth about $31,000. Your Advocates Ltd. LLP increased its holdings in Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. FPC Investment Advisory Inc. acquired a new stake in shares of Humana in the fourth quarter valued at $27,000. Finally, Centricity Wealth Management LLC purchased a new position in shares of Humana in the fourth quarter valued at approximately $30,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.